# The Interplay Between Immunological and Inflammatory Markers as Key Prognostic Indicators in Elderly Patients with COVID-19

## TL;DR

This study explores how immune and inflammation markers predict outcomes in elderly patients with COVID-19.

## Contribution

The study identifies specific immunological and inflammatory markers as potential prognostic indicators in elderly COVID-19 patients.

## Key findings

- Lymphopenia and neutrophilia are common in elderly patients with elevated C-reactive protein levels.
- Lymphocytes reduce mortality risk by 14.4%, while higher platelet-large cell ratio is linked to increased mortality.
- Inflammatory markers correlate with discharge status or death in elderly COVID-19 patients.

## Abstract

Background: The COVID-19 pandemic has disproportionately affected the elderly population, with inflammation and impaired immune response being key drivers of disease progression. Clinicians require predictive models integrating immunological and inflammatory biomarkers to optimize risk stratification in this vulnerable group. Methods: We retrospectively analyzed 1429 elderly patients (aged >60 years) admitted with COVID-19 between March 2020 and August 2022. Demographic, clinical, and laboratory data were collected at admission. Correlation and regression analyses were performed to assess the prognostic significance of hematological and inflammatory markers. Results: Lymphopenia and neutrophilia were predominant findings, frequently associated with elevated C-reactive protein levels. Correlation analyses revealed significant associations between inflammatory markers and discharge status or death, while lymphocytes exerted a protective effect, reducing mortality risk by 14.4%. Notably, a higher platelet-large cell ratio (PLCR) was linked to increased mortality, suggesting an important contribution of thrombosis to severe COVID-19. Conclusions: Our findings indicate that immunological and inflammatory markers may serve as significant predictors of outcomes in elderly COVID-19 patients. While the predictive power of the model remains limited, these biomarkers can contribute to a better understanding of patient trajectories and may inform therapeutic strategies.